Insights into Crystal Growth and Polymorphism in Active Pharmaceutical Ingredients: Investigating the Role of Specific Interactions for Polymorphic Stability and Transformations using Molecular Simulation
2026 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]
In the manufacturing of pharmaceutical products, polymorphism - the ability of the active pharmaceutical ingredient (API) to crystallize in several structures with different physicochemical properties - constitutes a major problem. Transitions between different polymorphic forms can occur in the primary crystallization step, but also at multiple points in the secondary processing workflow, as the compounds come into contact with different solvents or are exposed to thermal and mechanical stresses. Mechanistic information is not always easy to obtain due to the variety of conditions and unsystematic nature of the polymorph search.
In this thesis, the possibilities of using molecular simulation as a tool in the study of API polymorphism are evaluated on the case of carbamazepine. Special attention is placed on the importance of specific interactions as driving forces of the transformations between forms.
In the case of the polymorphic transformation of anhydrous carbamazepine in aqueous systems, the driving force for crystal growth on the main surfaces of the polymorphs is quantified and linked to the polarity of the part of the molecule in contact with the solvent. Defect growth is also predicted for a number of the evaluated surfaces.
Next, the reliability of simulation methods in the prediction of the equilibrium solubility is explored on the example of several APIs of varying flexibility. Problems in the accuracy of these methods can be attributed to the description of the molecular interactions in the solid state for more rigid molecules, such as carbamazepine. While the solution state seems to be modeled adequately for these compounds, the description of the interactions for larger and more flexible molecules with the solvent shows a need for further refinement.
Exposure to solvent can often trigger a solution-mediated polymorphic transition from a metastable form to the thermodynamically stable form. The mechanism of this transition is investigated for carbamazepine by exploring both the dissolution at the main faces of the metastable crystal and the behavior of the molecules in solution. It is found that both the type of solvent used and the crystallographic facet play a role in the dissolution process. The interactions of carbamazepine in solution suggest the formation of a possible precursor of the thermodynamically stable form in certain solvents, which might drive its nucleation.
The effect of mechanical stress on the stable form is explored in a separate study, since it has been shown to convert to another metastable form in ball milling, a common step in manufacturing. The microscopic changes in structure under high-pressure shear are found to depend on the magnitude of pressure, shearing speed and the crystallographic facet that is sheared. Evidence is found for the amorphization of the stable form under shear stress, but the retention of certain dimer motifs seen in both the stable and the metastable form suggests that there may be some structural matching facilitating the polymorphic transition.
Since the methodologies used in these studies are easily transferable to other active ingredients, we hope that they will guide future polymorph screening approaches and ultimately lead to an efficient and systematic way of evaluating the effect of polymorphism on pharmaceutical drug products.
Ort, förlag, år, upplaga, sidor
Stockholm: Department of Chemistry, Stockholm University , 2026. , s. 101
Nyckelord [en]
Polymorphism, Active Pharmaceutical Ingredients, Molecular Dynamics, Carbamazepine
Nationell ämneskategori
Fysikalisk kemi
Forskningsämne
fysikalisk kemi
Identifikatorer
URN: urn:nbn:se:su:diva-256721ISBN: 978-91-8107-676-9 (tryckt)ISBN: 978-91-8107-677-6 (digital)OAI: oai:DiVA.org:su-256721DiVA, id: diva2:2072264
Disputation
2026-09-08, Magnélisalen, Kemiska Övningslaboratoriet, Svante Arrhenius väg 16B, Stockholm, 13:00 (Engelska)
Opponent
Handledare
2026-08-142026-06-152026-08-06Bibliografiskt granskad
Delarbeten